menu search

Nexcella, immix biopharma subsidiary, to present at the bank of america 2023 healthcare trailblazers private company conference

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical...

September 7, 2023, 12:41 pm

nexcella appoints mary sue coleman, former johnson & johnson independent director, to board of directors

Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-201...

June 16, 2023, 1:48 pm

nexcella announces commencement of nxc-201 engineering batches at its u.s. car-t manufacturing site

U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineeri...

May 26, 2023, 1:58 pm

Immix biopharma subsidiary nexcella announces commencement of nxc-201 engineering batches at its u.s. car-t manufacturing site

U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineeri...

May 26, 2023, 1:53 pm

nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

nexcella announces late-breaking nxc-201 clinical data abstract accepted for oral presentation at the 26th annual meeting of the american society of gene and cell therapy (asgct)

•Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023 LOS ANGELES, May 04, 202...

May 4, 2023, 4:35 pm

Nexcella, inc. presents 42-patient interim data, with 90% overall response rate in relapsed or refractory multiple myeloma at nxc-201 therapeutic dose from its phase 1 expansion trial at the 5th europ

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 re...

February 9, 2023, 1:05 pm

Nexcella, inc announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car t-cell meeting

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:05 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm

Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:00 pm


Search within

Pages Search Results: